METHOD FOR TREATING DERMATITIS

Abstract

The present invention relates to methods for treating dermatitis and the use of a β-1 adrenoceptor antagonist in manufacturing a pharmaceutical composition for treating dermatitis. The methods comprise the step of administering the pharmaceutical composition comprising a therapeutically effective amount of β-1 adrenoceptor antagonist to a subject in need thereof.

Description

Claims

1. A method of treating dermatitis, comprising the step of administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of the β-1 adrenergic receptor antagonist.

2. The method according to claim 1, wherein the dermatitis is atopic dermatitis (eczema).

3. The method according to claim 1, wherein the dermatitis is induced by an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).

4. The method according to claim 1, wherein the dermatitis is steroid-resistant.

5. The method according to claim 1, wherein the dermatitis is seborrheic dermatitis.

6. The method according to claim 1, wherein the β-1 adrenergic receptor antagonist is selected from atenolol, betaxolol, bisoprolol, esmolol, acebutolol, metoprolol, nebivolol, or any combination thereof.

7. The method according to claim 1, further comprising the step of administering steroid, anti-histamine, immunomodulator, antibiotic, light therapy, or any combination thereof.

8. The method according to claim 7, wherein the immunomodulator is cyclosporine, tacrolimus or pimecrolimus.

9. The method according to claim 1, wherein the pharmaceutical composition is substantially free of an antibody.

10. The method of claim 1, wherein the pharmaceutical composition is substantially free of an antibody against IL4RA or IL-25.